BioCentury | Aug 1, 2020
Product Development

July 31 Quick Takes: FDA approves MorphoSys’ tafasitamab; Truvian, AbbVie, Boehringer, Lilly, Alector, Henlius-Accord, Ascletis, Roche, Merck

MorphoSys follows Kress’ first big deal with U.S. approval FDA granted accelerated approval to Monjuvi tafasitamab-cxix from MorphoSys AG (Xetra:MOR; NASDAQ:MOR) and Incyte Corp. (NASDAQ:INCY) in combination with lenalidomide to treat patients with relapsed or...
BioCentury | Jul 23, 2020

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | Jul 6, 2020
Product Development

July 6 Quick Takes: Cellectis CAR T trial halted; plus data readouts from Bellus, ObsEva, Idorsia, and more

Patient death prompts Cellectis trial halt  FDA placed a clinical hold on an allogeneic CAR T therapy trial to treat multiple myeloma from Cellectis S.A. (NASDAQ:CLLS; Euronext:ALCLS) after a patient who received the second-level dose...
BioCentury | Jun 18, 2020

June 17 Quick Takes: Constellation, Celldex raise follow-ons; plus CureVac quiet on IPO chatter and venture cash for GreenLight, TILT, DiogenX

Constellation raises close to $200M  Cancer epigenetics company Constellation Pharmaceuticals Inc. (NASDAQ:CNST) raised $192.5 million in a bumped-up follow-on Tuesday through the sale of 5.5 million shares at $35. The price is a 7% discount...
BioCentury | Jun 18, 2020
Emerging Company Profile

Lassen emerges from Frazier with over $31M and a mAb for fibrosis and cancer

After incubating in Frazier for a year and half, Lassen emerged from stealth Wednesday with a preclinical program targeting the IL-11 receptor that could be applied to both fibrosis and cancer and enough funds to...
BioCentury | Jun 17, 2020

With Ideaya deal, GSK bulks up synthetic lethality side of oncology business

A deal with Ideaya gives GSK a path to growing its synthetic lethality pipeline, a corner of the pharma’s cancer rebuild still primarily centered around PARP inhibitor Zejula. On Tuesday, GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and...
BioCentury | Jun 16, 2020

eTheRNA’s €34M series B to support different take on COVID-19 vaccine, build out core cancer pipeline

The series B round for eTheRNA will fund the Belgian company’s core immuno-oncology pipeline as well as its different mRNA approach to combat the threat of coronaviruses. eTheRNA immunotherapies N.V. said Tuesday it raised €34...
BioCentury | Jun 11, 2020

Prism’s peptide mimetic platform finds second discovery partner

Prism has closed a deal with its second large pharma partner, agreeing to collaborate with Boehringer to discover multiple compounds using its peptide mimetic platform. Financial terms and therapeutic focus of Monday’s deal are undisclosed....
BioCentury | Jun 3, 2020
Politics, Policy & Law

Biopharma community joins call for solidarity, denounces systemic racism

The biopharma industry stood up to be counted, with top pharmas, biotechs and VCs issuing public statements of solidarity as protests in the wake of George Floyd’s death continued Tuesday. The CEOs and other leaders...
BioCentury | May 23, 2020
Product Development

Hot topics at ASCO 2020

Center stage at this year’s virtual ASCO meeting are a series of hot topics that demonstrate the transformative potential of a single data readout or regulatory update. Areas to watch include next-generation checkpoint targets, where...
Items per page:
1 - 10 of 2327